Trials / Completed
CompletedNCT00000451
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 198 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sertraline | 16 week outpatient study |
| DRUG | naltrexone | 16 week outpatient study |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2005-08-01
- Completion
- 2005-11-01
- First posted
- 1999-11-03
- Last updated
- 2013-01-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00000451. Inclusion in this directory is not an endorsement.